

TABLE 1. Characteristics of 16 studies each representing different childhood cancer cohorts in the Nordic countries including descriptive information on study participation, cancer diagnosis, follow-up time, age at diagnosis and at follow-up, and type of clinical examination and duration

Study number and first author	SPR (Accepted /invited)	Study completers	Study dropouts	Cancer diagnosis	Median follow-up time in years (range)	Age at diagnosis (range)	Age at follow-up (range)	Clinical examination and duration (<3 hours or >3 hours)
1 Järvelä et al. [1]	21/77 27% (18%-39%)	21	0	ALL	15.9 (11.3-21.4)	4.9 (1.6-12.9)	22.8 (16.7-30.3)	Exercise test, echocardiography (>3h)
2 Romerius et al. [2]	161/407 40% (35%-44%)	151	16 (+10 excluded)	TC, L, ALL/AML, BT, WT	7.5	10.0 (0.1-17)	30 (20-46)	Semen sample (<3h)
3 Einar-Jon et al. [3]	15/15 100% (78%-100%)	15	NA	BT, WT, OS, RS, NB, HB	9.1 (0.8-16.5)	4.3 (0.4-18.0)	14.1 (11.1-30.1)	Audiometric evaluation (<3h)
4 Frisk et al. [4]	18/25 72% (51%-88%)	18	NA	ALL, L	18.2 (10.3-22.1)	9.8 (5.6-18.3)	27.5 (17. 3-37.1)	Endocrinologic evaluation (>3h)
5 Hess et al. [5]	130/223 58% (52%-65%)	128	2 excluded	L	20 (7-37)	14 (0-18)	32 (19-55)	Semi-structured interview, clinical examination (>3h)
6 Jahnukainen et al. [6]	51/75 68% (65%-85%)	51	NA	ALL	20 (11-30)	5 (1-15)	29 (26-38)	Testicular endocrine function (<3h)
7 Pietila et al. [7]	57/75 76% (65%-85%)	52	5 excluded	BT	7.5 (1.5-15.5)	6.0 (0.1-15.5)	14.2 (3.8-28.7)	Cognitive examination, neurologic test Cognitive test, neurologic examination (>3h)
8 Fjalldal et al. [8]	42/53 79% (66%-89%)	42	0	BT	20 (1-40)	Female 12 (3-20) Male 12 (3-22)	Female 28 (18-57) Male 19 (17-57)	Cognitive test (>3h)
9 Follin et al. [9]	51/58 88% (77%-95%)	44	7 excluded	ALL	19 (9-27)	3.9 (1-17)	25 (19-32)	Endocrinologic evaluation (>3h)
10 Molgaard-Hansen et al. [10]	102/137 74% (66%-82%)	102	0	AML	11 (4-25)	3.0 (0-15)	16.2 (5-36)	Pubertal development, blood samples (>3h)

11	Ylanen et al. [11]	62/85 73% (62%-82%)	62	0	ALL, AML, HL, NH, NB, WT, RS	7.7 (4.9-18)	3.0 (0-13.8)	Male 14.9±2.9 Female 14.4 ±3.4	Cardiac MR (<3h)
12	Vatanen et al.[12]	19/24 79% (58%-93%)	19	0	NB	20.1 ±4.8	NA	22.7 ± 4.9	U Ultrasound of Arteries (<3h)
13	Einarsson et al. [13]	15/15 100% (78%-100%)	15	0	OS, T, NB, WT	19.7 (0.1-17)	10.7 (0.1-17.0)	Hearing impaired 27.5 (17.7- 33.9) Normal hearing 23.7 (15.5-30.9)	A Audiometric evaluation (<3h)
14	Remes et al. [14]	74/127 58% (49%-67%)	73	1	BT	18.9 ±6.1	8.3±4.9	28.4 ± 6.8	C Dual X-ray absorptiometry (>3h)
15	Lofstad et al. [15]	36/51 71% (56-83%)	36	0	ALL	7.7 (4.3-12.4)	3.6 (1.5-7.5)	11.5 (8.4-15.3)	Neuropsychological testing (>3h)
16	Stensvold et al.[16]	50/63 79% (67%-89%)	50	0	BT	20 (3.2-41)	7.1 (0-19)	26 (5.5-52)	I Interview, clinical examination, audiometry, neuropsychological assessment (>3h)

Abbreviations: Study participation rate (SPR), Acute lymphoblastic leukemia (ALL), testicular cancer (TC), lymphoma (L), acute myeloid leukemia (AML), brain tumor (BT), Wilms tumor (WT), osteosarcoma (OS), neuroblastoma (NB), rhabdmyosarcoma (RS), hepatoblastoma (HB), Hodgkin lymphoma (HL), non-Hodgkin lymphoma (NH), teratoma (T), not assessed (NA)